ACM
CRNX

Aster Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Aster Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.04K Buy
+215
New +$7.99K ﹤0.01% 689
2026
Q1 		– Sell
-158
Closed -$7.36K – 939
2025
Q4 		$7.36K Buy
+158
New +$7.03K ﹤0.01% 805
2025
Q3 		– Sell
-260
Closed -$7.48K – 1042
2025
Q2 		$7.48K Buy
+260
New +$8.03K ﹤0.01% 823

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aster Capital Management's CRNX Position: Q2 2026 in Review

Aster Capital Management opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 215 shares worth $8.04K. The stake represents ﹤0.01% of the portfolio and ranks #689 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in CRNX as recently as Q4 2025.

Aster Capital Management first reported a position in CRNX in Q2 2025 and has held it in 3 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Aster Capital Management held 215 shares of Crinetics Pharmaceuticals worth $8.04K as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Aster Capital Management position in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Aster Capital Management's portfolio in Q2 2026, its #689 holding.
  • Aster Capital Management first reported a position in Crinetics Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.